EP2473178A2 - Compositions utilisables dans le cadre du traitement des hémorroïdes et de maladies associées - Google Patents

Compositions utilisables dans le cadre du traitement des hémorroïdes et de maladies associées

Info

Publication number
EP2473178A2
EP2473178A2 EP10760244A EP10760244A EP2473178A2 EP 2473178 A2 EP2473178 A2 EP 2473178A2 EP 10760244 A EP10760244 A EP 10760244A EP 10760244 A EP10760244 A EP 10760244A EP 2473178 A2 EP2473178 A2 EP 2473178A2
Authority
EP
European Patent Office
Prior art keywords
extract
opuntia ficus
polysaccharides
cladodes
ficus indica
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10760244A
Other languages
German (de)
English (en)
Other versions
EP2473178B1 (fr
Inventor
Luisa Rizza
Salvatore Munafo'
Alberto Serraino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIONAP Srl
Original Assignee
BIONAP Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIONAP Srl filed Critical BIONAP Srl
Publication of EP2473178A2 publication Critical patent/EP2473178A2/fr
Application granted granted Critical
Publication of EP2473178B1 publication Critical patent/EP2473178B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention refers to new pharmaceutical, nutraceutical, health foods and medical device compositions for the the prevention or the treatment of hemorrhoids, their complications and related illnesses.
  • compositions for oral use or topical application comprising polysaccharides from Opuntia ficus indica cladodes extract in combination with extracts from Olive leaf (Olea europeaea corticoids) and optionally with local anesthetics, vasoconstrictors, astringent substances and/or with plant extracts having anti-oxidant or anti-inflammatory effect as well as those from Capparis Spinosa buttons, anthocianosides from red oranges, black rice or from other natural sources and their combinations, useful for prevention and therapy of hemorrhoidal disease and related illnesses.
  • polysaccharides from Opuntia ficus indica cladodes extract in combination with extracts from Olive leaf (Olea europeaea corticoids) and optionally with local anesthetics, vasoconstrictors, astringent substances and/or with plant extracts having anti-oxidant or anti-inflammatory effect as well as those from Capparis Spinosa buttons, anthocianosides from red orange
  • Hemorrhoids are anatomical angio-cavernous structures of the anal canal present in utero into adult life that complete liquid and gas continence through blood afflux and deflow, growing in their volume (closing anal canal lumen) because of the arterial afflux, and reducing in their volumee (reopening the anal canal lumen) because of venous deflow.
  • Hemorrhoidal disease consists in partial anal canal coating sliding down: rectal mucosa slides down pushing outward internal hemorrhoids which consequently push outward external hemorrhoids.
  • Hemorrhoids may have hereditary or constitutional etiopathogenesis: however, the cause underlying their development is still unclear. Probably, considering the recurrence of the disease in several family members, sometimes genetic factors are involved. Constipation can make hemorrhoids more serious, because of the irritating effect that hard stools and strong defecation effort may have on the anal canal.
  • Constipation that may begin or worsening during pregnancy frequently causes hemorrhoidal disease onset during pregnancy.
  • hemorrhoids are often related to anal fissures, tears or ulcers that occur at the end of anal canal because of the strong defecation effort that may determine tissue damage in this region.
  • Hemorrhoidal disease is very widespread, affecting, both in North America and in Europe, 1 to 10 millions people (Holzheimer RG, Eur J Med Res, 26 JAN 2004; 9 (1 ): 18-36, Hemorrhoidectomy: indications and risks). Hemorrhoidal disease is usually treated with strict dietary and behavioural rules and with pharmacological treatments. Most of the people suffering from hemorrhoidal disease are able to live with this disease thank to strict dietary habits and lifestyle, hygiene and/or the use of topical application of products containing steroids (because of their anti-inflammatory action) and local anesthetics.
  • dietary and behavioural rules may be added with a pharmacological treatment with topical application of products (creams, ointments, unguents, foams and suppositories) containing steroids, that acts on pain and swelling, and/or local anesthetics, that relieve itching and pain.
  • products creams, ointments, unguents, foams and suppositories
  • steroids that acts on pain and swelling, and/or local anesthetics, that relieve itching and pain.
  • these products are recomended for brief-term axes, because long-term treatment with these substances may determine irritation at the application site, particularly at level of rectal and anal mucosa.
  • compositions able to reduce the inflammatory component characteristic of hemorrhoidal disease and of its complicances are now identified. These compositions have also a mucoprotective effect and then they are even able to protect anal and rectal mucosa from the irritative effect of substances that may be present in faeces causing pain in the acute phase of the disease and making easy or quickening its relapse.
  • compositions are characterised by containing polysaccharides from Opuntia Ficus Indica cladodes extract in combination with Olea europaea leaf extract having anti-oxidant and/or anti-inflammatory action, and optionally with Capparis Spinosa buttons extracts, anthocianosides from red oranges, black rice or from other natural sources and their combinations, for preventing and treating hemorrhoidal disease, its complicances and related illnesses.
  • medical device refers to an "Active medical device” (class I) in accordance with the Directive 93/42/EEC Annex IX classification.
  • Opuntia Ficus Indica (Nopal) is a plant belonging to Cactaceae, native to Mexico and to south-west United States, but widespread even in self-sown Mediterranean vegetation.
  • Opuntia ficus indica fruits have marked anti-oxidant properties (Tesoriere and al., Supplementation with cactus pear (Opuntia ficus-indica) fruit decreases oxidative stress in healthy humans: a comparative study with vitamin C, Am J Clin Nutr. 2004 Aug; 80(2): 391-395); 2) an Opuntia ficus indica extract is effective in the alcohol hangover therapy (Wiese J and al., Effect o/Opuntia Ficus Indica on symptoms of the alcohol hangover, Arch Intern Med.
  • Opuntia cladodes essentially formed by a polymer of galactose, arabinose and other sugars, has swallowed fat and sugars ligand properties (making so them impossible to be absorbed) leading to good results on glyco-lipidic metabolisms and on metabolic syndrome;
  • Opuntia ficus indica cladodes mucilages and pectins proved to be gastro-protective in experimental animal models (Vazquez- Ramirez R.
  • Trombetta and al. (Trombetta D. and al., Effects of polysaccharides from Opuntia Ficus Indica (L.) cladodes on the healing of dermal wounds in the rat, Phytomedicine, 13 (2006) 352-358) observed that polysaccharides from Opuntia ficus indica cladodes extract have cutaneous healing effect acting on cellular matrix and modulating laminin laying down.
  • Opuntia ficus indica cladodes produce an anti- inflammatory effect in a synergistic way with Olea europaea leaf extract and that this effect is increased by the addition of Capparis Spinosa buttons extracts, anthocianosides from red oranges, black rice or from other natural sources and their combinations, whereby the Opuntia ficus and Olea europea extracts are conveniently used in combination for preventing and treating hemorrhoidal disease, its complicances and related illnesses.
  • the Opuntia ficus and Olea europea extracts are provided in the form of a combined preparation for simultaneous or separate use in the prevention and treatment of hemorrhoidal disease, complications thereof and related illnesses, and particularly for use in the mucoprotection of anal and rectal mucosa and to prevent or treat inflammation of the same.
  • polysaccharides from Opuntia ficus indica cladodes may be in mucilage form, obtained by a pressing process or by treatment in water at room temperature.
  • cladodes juice is centrifuged and the supernatant is subjected to ultrafiltration leading to an aqueous solution enriched in the MW > 10 4 Da polysaccharides fraction which may be concentrated and then dried.
  • Polysaccharides content in Opuntia ficus indica cladodes extract is from 1 up to 70%.
  • Olea europaea leaf may be extracted with aqueous or hydro-alcoholic solvents (10-80% ethanol), at room temperature or at 60-70°C.
  • the hydro-alcoholic extraction may be repeated in order to obtain an higher biophenols concentration.
  • the aqueous solvent is removed in vacuum at 40°C.
  • a higher biophenols concentration may be obtained loading the dried extract on resins, preferably styrenic resins, and eluting with ethanol: water 50:50 (v/v).
  • Olea europaea leaf extract contains phenols (tyrosol, hydroxytyrosol and their derivatives), cinnamic acids, flavonoids (as well as apigenin, luteolin and their glucosidic derivatives, rutin, quercetin), lignans, secoiridoids (as well as oleurosid, oleuropein and their derivatives, elenolic acid), and is characterised by a particular content in polyphenols: flavonoids (apigenin, luteolin and their derivatives) 2-40% (w/w), oleuropein 0.5-10% (w/w) and hydroxytyrosol and derivatives 1-30% (w/w).
  • the present invention also refers to pharmaceutical, dermocosmetic, nutraceutical, health foods and medical device compositions for oral administration, topical or rectal application, comprising polysaccharides from Opuntia ficus indica cladodes extract in combination with Olea europaea leaf extract having anti-oxidant and/or anti-inflammatory action, and optionally with Capparis Spinosa buttons extracts, anthocianosides from red oranges, black rice or from other natural sources and their combinations, for preventing and treating hemorrhoidal disease, its complicances and related illnesses.
  • the terms “combination” and “combined preparation” are used for both fixed and therapeuthic combinations of the extracts or the actives considered.
  • the extracts or the actives are contained in the same composition, with vehicles, excipients or other ingredients useful for the proposed applications; in the second case (therapeutic combination) the active ingredients may be administered or applied in separate compositions as well as through different administration routes, in order to obtain a combined therapeutic effect.
  • the synergistic effect due to the combination of the considered actives or extracts allows advantageously to reduce the inflammatory component combined with hemorrhoidal disease, and, having the considered compositions also a mucoprotective effect, they are able, at the same time, to protect the rectal mucosa, determining a rapid resolution of the synthomps with an higher grade of therapeutic safety, a very important factor in case of repeated treatments, in general for topical treatments and in particular for pregnant or post-partum women and elderly people treatment.
  • Object of the invention is therefore providing pharmaceutical, dermocosmetics, nutraceutical, health foods and medical device oral or topical (rectal) compositions, comprising polysaccharides from Opuntia ficus indica cladodes extract in fixed or therapeutic combination with Olea europaea leaf extract and optionally with Capparis Spinosa buttons extracts, anthocianosides from red oranges, black rice or from other natural sources and their combinations, for preventing and treating hemorrhoidal disease, its complicances and related illnesses (e.g. anal fissures), for preventing relapse in same disease and for protecting rectal mucosa from the irritative effect of some food components that may be present in faeces.
  • DESCRIPTION OF THE FIGURES DESCRIPTION OF THE FIGURES
  • Figure 1 represents a scheme of the in vitro mucoadhesion model
  • FIG. 2 graphs the comparison of the mucoadhesion percentage values (inhibition percentage of lectin binding after treatment) for Opuntia ficus indica cladodes extract versus hyaluronic acid in an in vitro mucoadhesion model on epithelial rectal mucosa cells;
  • FIG. 3 graphs the ICAM- 1 inflammation marker inhibition percentage values determined by polysaccharides from Opuntia Ficus Indica cladodes extract and by Olea europaea leaf extracs on Cacol cells treated with pro-inflammatory substances;
  • FIG. 4 graphs the IL-8 inflammation marker inhibition percentage values determined by polysaccharides from Opuntia ficus indica cladodes extract and by Olea europaea leaf extracs on Cacol cells treated with pro-inflammatory substances.
  • the present invention provides pharmaceutical, dermocosmetics, nutraceutical, health foods and medical device compositions for oral administration or for topical or intrarectal application for treating hemorrhoidal disease and related illnesses (as well as anal fissures) and for relapse prevention of the same pathologies, comprising polysaccharides extracted from Opuntia ficus indica cladodes, optionally supported on maltodextrins up to 50% (w/w), in fixed or combination therapy with Olea europaea leaf extract having an anti-oxidant and anti-inflammatory action and optionally with Capparis Spinosa buttons extracts, anthocianosides from red oranges, black rice or from other natural sources and their combinations, for preventing and treating the same diseases.
  • Actives from Olea europaea leaf extract useful for the claimed compositions may comprise, as non-limiting examples: phenols, (as well as tyroxol, hydroxytyrosol and their derivatives), cinnamic acid, flavonoids (as well as apigenin, luteolin and their glucosidic derivatives, rutin, quercitin), lignans, secoiridoids (as well as oleurosid, oleuropein and their derivatives, elenolic acid).
  • compositions may be liquid, solid or semi-solid, able to be administered per os (e.g. oral solutions, oral suspensions, oral emulsions, tablets, powders and tablets to extemporarily prepare oral solutions, suspensions or emulsions) or to be applied topically (e.g. creams, ointments, foams, suppositories, gel, spray).
  • os e.g. oral solutions, oral suspensions, oral emulsions, tablets, powders and tablets to extemporarily prepare oral solutions, suspensions or emulsions
  • topically e.g. creams, ointments, foams, suppositories, gel, spray.
  • compositions may moreover include preservatives, ionic and non ionic buffered agents and additives normally used in preparing oral or topical compositions.
  • compositions may moreover comprise other natural components useful for the tratment of the mentioned pathologies such as local anesthetics and vasoconstrictive agents (e.g. flavonoids from Aesculus hippocastanum extracts, having anti-inflammatory and vasoconstrictive effect, and escin, the active principle from Aesculus hippocastanum having vasoprotective, anti-edemigenous and anti-oxidant action and able to stabilize vascular resistance and permeability, currently used in topical and systemic products; extract from Ruscus aculeatus, rich in substances similar to those found in hippocastanum, able to determine a venotonic, vaso-constrictive and anti-inflammatory action observed in several clinical studies, and polyphenols and flavonoids extract from Cupressus, having anti-inflammatory and vaso-constrictive action).
  • local anesthetics and vasoconstrictive agents e.g. flavonoids from Aesculus hippocastanum extracts, having anti-inflammatory and vasoconstrictive effect
  • cortisone may delay the healing process and therefore it is better using products free of cortisone.
  • the most common solvent for liquid compositions, suspensions or emulsions is water or an aqueous solution containing components useful for oral or topical use.
  • Topical compositions may contain surfactants (e.g. glyceryl monostearate), fat substances (as suppository base), ointment bases (e.g. stearic acid, stearyl alcohol or lanolin), suspending agents (e.g. talc, silicic anhydride), antimicrobial preservatives (e.g. methyl p-hydroxybenzoate, propyl p-hydroxybenzoate or butyl p-hydroxybenzoate), lubricants (e.g.
  • Mucilage is deemed to be composed of 1,4-a-D -galactopyranosyluronic acid and 1,2- ⁇ - ⁇ , - rhamnopyranosyl residues to which are attached short chains of ⁇ , ⁇ - ⁇ -D -galacto-pyranosyl residues at position 4 of all of the rhamnopyranosyl residues.
  • Most of the galactosyl residues are branched at O-3, or at O-4, which mainly carry arabinofuranosyl and xylopyranosyl residues.
  • Mucilage from Opuntia ficus indica cladodes extract is separated by a simple squeezing process (D. Trombetta et al. Effect of polysaccharides from Opuntia ficus-indica (L.) cladodes on the healing of dermal wounds in the rat. Phytomedicine (2006) 13 : 352-358) or by treatment with water (R. Vazquez- Ramirez et al. Reversing gastric mucosal alterations during ethanol-induced chronic gastritis in rats by oral administration of Opuntia ficus-indica mucilage. World J Gastroenterol (2006) 12(27):43 18-4324).
  • Opuntia ficus indica cladodes are washed and cutted into pieces of about 10 cm and then are squeezed by using an hydraulic forging press.
  • the juice obtained by cladodes squeezing is centrifuged for 15 min at 5000 g and supernatant is ultrafiltered. In this way, an aqueous solution enriched in polysaccharides fraction with MW > 10 4 Da is obtained. This aqueous solution is then concentrated at low pressure and at 35-40°C, and is subsequently dried by spry-drying or freeze-drying.
  • Opuntia ficus indica cladodes extract polysaccharides fraction confirmed the presence of arabinose, rhamnose, xylose, galactose and galacturonic acid (D. McGarvie, H. Parolis, Methylation analysis of the mucilage of Opuntia ficus indie. Carbohydrate Research, (1981) 88: 305-3 14).
  • NMR Nuclear Magnetic Resonance
  • Polysacchardes content in Opuntia ficus indica cladodes extract is from 1 to 70% w/w. Olea europaea leaf extract
  • Olea europaea leaf extract has a characteristic composition in biophenols, containing simple phenols (tyrosol, hydroxityrosol and derivatives), flavonoids (apigenina, luteolina and their glucosides) and secoridoids (oleuropein and derivatives).
  • Biophenols are extracted from olive leaf using aqueous or hydro-alcoholic solvents containing ethanol from 10 to 80% v/v (Lee O.H. et al. Assessment of phenolics-enriched extract and fractions of olive leaf and their antioxidant activities Bioresour Technol (2009) Epub ahead of print; Mylonaki S. et al. Optimisation of the extraction of olive (olea europaea) leaf phenolics using water ⁇ ethanol-based solvent systems and response surface methodology. Anal Bioanal Chem. (2008) 392(5):977-85). Extraction processes are generally carried out at room temperature for avoiding changes or degradation in active susbtances, but in some cases extraction processes may be carried out at temperature up to 60-70°C.
  • Biophenols extraction from plant matrix may be carried out even using microwaves (Japon-Lujan R, Luque de Castro MD. Small branches of olive tree: a source of biophenols complementary to olive leaf. J Agric Food Chem. (2007) 30;55(1 1):4584-8), ultrasound (Vassiliki T Papoti, Maria Z. Tsimidou. Impact of sampling parameters on the radical scavening potential of olive (Olea europaea L.) leaf. J Agric Food Chem 2009, 57, 3470-3477), or superheated liquid extraction (Japon-Lujan R, Luque de Castro MD. Superheated liquid extraction of oleuropein and related biophenols from olive leaf. J Chromatogr A. (2006) 1 136(2): 185-91), greatly reducing solvent and plant matrix contact time (from 3 hours to 10 minutes).
  • Olea europaea leaf are dried, cutted and then entracted with an ethanol/water 50:50 (v/v) solution, at room temperature for 12 hours.
  • the extraction process is carried out with a 1 :5 (g/ml) drug:solvent ratio.
  • the extract is removed and the leaf undergo a second hydroalcoholic extraction process at the same conditions.
  • the extracts are then mixed and the solvent is removed by concentration in vacuum at 40°C.
  • the extract is adsorbed on styrenic resins and biophenols and then eluted with an ethanol/water 50:50 (v/v) solution.
  • the extract obtained contains: flavonoids (apigenin, luteolin and their derivatives) 2-40%, oleuropein 0.5-10% and hydroxityrosol and derivatives 1-30%.
  • Opuntia Ficus Indica extracted polysaccharides may be present from 0.5 to 50% of the total compositions, while the other actives may be present from 1 to 30% (w/w or w/v).
  • the claimed substances are individually applied in the dietary field, so they are safe even for delicate patient's categories, as well as elderly people, children or pregnant women.
  • compositions may contain substances from natural sources having astringent action (as well as Hamamelis virginiana extract, zinc oxide or calamine), vasocostrictive agents (e.g. phenylefrine HC1, ephedrine sulfate, epinephrine and epinephrine HC1), steroidal anti-inflammatories (e.g. hydrocortisone), fitosteroids (e.g. flavio lignans, enterolignans, coumestrol, equol, beta-sitosterol, ginsenoides), local anesthetics (e.g.
  • vasocostrictive agents e.g. phenylefrine HC1, ephedrine sulfate, epinephrine and epinephrine HC1
  • steroidal anti-inflammatories e.g. hydrocortisone
  • fitosteroids e.g. flavio lig
  • mentioned components are used in their hydrosoluble form (e.g. esters or salts).
  • the present invention comprises the use of the described compositions for treating and preventing hemorrhoidal diesease relapses administering to a subject therapeutically effective amount of the compositions as defined above, optionally in combination with Capparis Spinosa buttons extracts, anthocianosides from red oranges, black rice or from other natural sources and their combinations, for preventing and treating the same diseases.
  • compositions according to the invention are reported in the following tables.
  • Example 2 In vitro determination of mucoadhesion of polysaccharides from Opuntia Ficus Indica cladodes
  • Treatment of mucosal cells with biotinylated lectin and streptavidin peroxidase determines a yellow colour of the sample; a pre-treatment of mucosal cells with a mucoadhesive substance, (30°C, for 15 minutes before the treatment with lectin), will hide the lectin binding site, reducing the final yellow colouring intensity.
  • Lectin is a protein contained in some plants of Leguminosae ⁇ Canavalia ensiformis), with high tendency to bind glucosidic and mannosidic residues of membrane glycoproteins; biotin (vitamin H) is bonded to lectin following its binding to streptavidin peroxidase that is added to cellular suspension to obtain the complex protein-glucose-lectin-biotin-streptavidin peroxidase.
  • o-pd o-phenylendiamine dihydrochloride
  • hydrogen peroxide By addition of o-phenylendiamine dihydrochloride (o-pd) and hydrogen peroxide to the cellular suspension, o-pd is oxidized by the complex protein- glucose-lectin-biotin-streptavidin peroxidase to 2,3-diaminophenazine, and the sample becomes yellow (Fig. 2).
  • the reaction is then blocked after 1 min adding H 2 SO 4 1M.
  • the colour intensity is read at the spectrofluorimeter and it is proportionally related to binding between lectin and glycosidic residues on cellular membrane.
  • Caco2 cells were manteined in Minimun Essential Medium (MEM) with 10% fetal calf serum, 100 U/ml penicillin and 100 ⁇ g/ml streptomycin at 37°C and 95 :5% air:CO 2 conditions. The medium was changed every 2-3 days. Twentyfour hours before treatment, cells were trypsinized, counted using an hemacytometer, centrifuged at 1500 rpm/5 min and resuspended in 2 ml 0,05 M TBS (Tris Buffered Saline) (pH 4).
  • MEM Minimun Essential Medium
  • TBS Tris Buffered Saline
  • Opuntia Ficus Indica cladodes polysaccharides and Olea europaea leaf extract.
  • Caco2 intestinal cells which are widely used to study gastro-intestinal tract functionality (Sambuy Y. et al., The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture -related factors on Caco-2 cell functional characteristics, Cell Biol Toxicol. 2005; 21(1): 1-26; Navarro-Peran E. e altri, The anti-inflammatory and anti-cancer properties of epigallocatechin-3-gallate are mediated by folate cycle disruption, adenosine release and NF-kappaB suppression, Inflamm Res. 2008 Oct 2) - were chosen for their morphological and biochemical characteristics, typical of intestinal enterocyte.
  • ICAM-1 intercellular adhesion molecule
  • IL-8 interleukin-8
  • ICAM-1 is an important factor involved in retention of T cells at the inflammed epithelium and represents a significant co-stimulatory signal for CD4 T and CD8 (Ramakers JD e altri, Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells. Lipids 2007; 42(8):687-98).
  • IL-8 is produced by monocytes, fibroblasts, endothelial and epithelial cells during inflammation disorders and is very important for T lymphocytes and neutrophyls recruitment (Vavricka SR e altri, hPepTl transports muramyl dipeptide, activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells, Gastroenterology 2004; 127(5): 1401-9).
  • IL- ⁇ interleukin- ⁇ ⁇
  • IFN- ⁇ interferon- ⁇
  • IL- ⁇ interleukin- ⁇ ⁇
  • IFN- ⁇ interferon- ⁇
  • Polysaccharides from Opuntia Ficus Indica cladodes and from Olea europaea leaf extracts were diluted at 100 mg/ml. From this solution, subsequent dilutions were obtained for cell culture treatments.
  • MEM Minimun Essential Medium
  • fetal calf serum 100 U/ml penicillin and 100 ⁇ g/ml streptomycin at 37°C and 95:5% air:CO 2 conditions.
  • the medium was changed every 2-3 days. Twentyfour hours before treatment, cells were trypsinized, counted using an hemacytometer, and then seeded in 96 well plates (for the ELISA test) and 100 mm Petri dishes (for the Western blot).
  • cells were treated with a mixture of IL- ⁇ ⁇ (lOng/ml) and IFN- ⁇ (200U/ml), and with polysaccharides from Opuntia Ficus Indica cladodes and/or with Olea europaea leaf extract at 200 ⁇ g/ml for 48 hours.
  • ICAM-1 The expression levels of ICAM-1 were determned by Western blot, while IL-8 was determined by ELISA test. The results were expressed as percentage of inflammation markers inhibition in cells treated with polysaccharides from Opuntia Ficus Indica cladodes and/or with Olea europaea leaf extract versus cells treated IL- ⁇ ⁇ and IFN- ⁇ .
  • Proteins were extracted from cells 48 hours after treatment, loaded on a
  • IL-8 was measured in the supernatant free from cells harvested 48 hours after treatment using an ELISA kit (Enzyme-Linked Immunosorbent Assay) able to specifically recognize the protein by antigen-antibody binding.
  • the complex is recognized and bound by a polyclonal antibody labeled with an enzyme. Calculating the enzyme activity after the addition of substrate, it is possible to have an estimate directly proportional to the amount of test antigen. Values are reported as pg/ml + SEM.
  • Olea europaea leaf extract determines an unexpected synergistic effect in the anti-inflammatory action of polysaccharides from Opuntia Ficus Indica cladodes extract, particularly a synergistic effect in reducing the expression of both the markers of inflammation ICAM- 1 and IL-8 induced in Caco2 cells by using proinflammatory substances.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques, nutraceutiques, des aliments de santé et des compositions associées à des dispositifs médicaux, contenant des polysaccharides issus des cladodes d'Opuntia Ficus Indica en association avec des extraits végétaux antioxydants et anti-inflammatoires, des extraits de feuilles d'olivier et de boutons de Capparis Spinosa, des anthocyanosides issus des oranges sanguines, du riz noir ou d'autres sources naturelles et des combinaisons de ceux-ci. Les compositions de l'invention peuvent être utilisées dans le cadre de la prévention et du traitement de la maladie hémorroïdaire et de maladies associées, et elles peuvent être appliquées par voie topique ou administrées par voie orale.
EP10760244.3A 2009-09-02 2010-09-01 Compositions utilisables dans le cadre du traitement des hémorroïdes et de maladies associées Active EP2473178B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2009A001523A IT1395509B1 (it) 2009-09-02 2009-09-02 Composizione per il trattamento della patologia emorroidaria e delle patologie correlate
PCT/EP2010/005346 WO2011026606A2 (fr) 2009-09-02 2010-09-01 Compositions utilisables dans le cadre du traitement des hémorroïdes et de maladies associées

Publications (2)

Publication Number Publication Date
EP2473178A2 true EP2473178A2 (fr) 2012-07-11
EP2473178B1 EP2473178B1 (fr) 2013-11-13

Family

ID=42102613

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10760244.3A Active EP2473178B1 (fr) 2009-09-02 2010-09-01 Compositions utilisables dans le cadre du traitement des hémorroïdes et de maladies associées

Country Status (9)

Country Link
US (1) US9028883B2 (fr)
EP (1) EP2473178B1 (fr)
CN (1) CN102548570B (fr)
BR (1) BR112012004714A2 (fr)
ES (1) ES2443574T3 (fr)
HK (1) HK1171677A1 (fr)
IT (1) IT1395509B1 (fr)
RU (1) RU2565397C2 (fr)
WO (1) WO2011026606A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140227198A1 (en) * 2013-02-13 2014-08-14 GRADS Holdings LLLP Shelf-stable olive extract-containing compositions and methods of use thereof
ITMI20132056A1 (it) * 2013-12-10 2015-06-11 Pharmaday Srl Composizioni per il trattamento delle afte e delle stomatiti aftose
CN104138397A (zh) * 2014-01-13 2014-11-12 北京德默高科医药技术有限公司 一种预防和辅助治疗痔疮的组合物
CL2014000243A1 (es) * 2014-01-30 2014-08-01 Univ Del Desarrollo Composición biocida para el control de plagas que afectan a abejas melíferas, que comprende un extracto soluble en agua de olea europea (olivo); uso de la composición; y método para controlar plagas que afectan a abejas.
MA39500A (fr) * 2014-03-06 2017-08-15 Bionap S R L Compositions à base d'extraits de plantes pour l'inhibition de la 5-alpha-réductase
US20170080040A1 (en) * 2014-05-15 2017-03-23 Livio Pesle Decoction of olive leaves
EP4282476A2 (fr) 2015-12-18 2023-11-29 Mary Kay Inc. Compositions cosmétiques topiques
ES2663574B1 (es) * 2016-10-13 2019-01-21 Laboratorios Cinfa S A Combinacion con funcion regenerativa de la funcion barrera de la piel
US20210251882A1 (en) * 2020-02-17 2021-08-19 Mary Kay Inc. Topical cosmetic compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1223866A (zh) * 1997-11-28 1999-07-28 李振起 痔疮散
US6228387B1 (en) * 2000-01-27 2001-05-08 Murray Borod Integrated comprehensive hemorrhoid treatment compositions and regimen
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US6365198B1 (en) * 2001-01-28 2002-04-02 Gulf Pharmaceutical Industries Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids
WO2002064537A1 (fr) * 2001-02-15 2002-08-22 Consejo Superior De Investigaciones Cientificas Procede d'obtention d'hydroxytyrosol purifie a partir de produits et de sous-produits derives de l'olivier
CN1827127A (zh) * 2005-03-03 2006-09-06 上海健奥生物科技有限公司 橄榄叶提取物的提取方法及工艺
CN100409873C (zh) * 2005-06-08 2008-08-13 胡硕泉 治疗痔疮脚气的中草药剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2011026606A2 *

Also Published As

Publication number Publication date
RU2565397C2 (ru) 2015-10-20
HK1171677A1 (en) 2013-04-05
ITMI20091523A1 (it) 2011-03-03
ES2443574T3 (es) 2014-02-19
US9028883B2 (en) 2015-05-12
RU2012107855A (ru) 2013-10-10
IT1395509B1 (it) 2012-09-28
BR112012004714A2 (pt) 2016-03-15
CN102548570A (zh) 2012-07-04
CN102548570B (zh) 2015-06-17
US20120183627A1 (en) 2012-07-19
WO2011026606A2 (fr) 2011-03-10
EP2473178B1 (fr) 2013-11-13
WO2011026606A3 (fr) 2011-06-23

Similar Documents

Publication Publication Date Title
EP2473178B1 (fr) Compositions utilisables dans le cadre du traitement des hémorroïdes et de maladies associées
Boudreau et al. An evaluation of the biological and toxicological properties of Aloe barbadensis (miller), Aloe vera
He et al. The genus Achyranthes: A review on traditional uses, phytochemistry, and pharmacological activities
Al-Snafi The pharmacology of Equisetum arvense-A review
Mukherjee et al. Phytochemical and therapeutic profile of Aloe vera
Cock The genus Aloe: Phytochemistry and therapeutic uses including treatments for gastrointestinal conditions and chronic inflammation
US20190008907A1 (en) Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases
Ercan et al. Potent therapeutic effects of ruscogenin on gastric ulcer established by acetic acid
CN103182023A (zh) 一种治疗慢性咽炎的药物及其制备方法
WO2019132625A1 (fr) Composition pour prévenir, améliorer ou traiter la dermatite atopique, contenant un extrait d'herbes mixte en tant que principe actif
Obidike et al. Microencapsulation enhances the anti-ulcerogenic properties of Entada africana leaf extract
Zorko et al. Efficacy of a polyphenolic extract from silver fir (Abies alba) bark on psoriasis: A randomised, double-blind, placebo-controlled trial
KR100483539B1 (ko) 아토피성 피부염의 예방 또는 치료용 조성물 및 그 제조방법
US20040265344A1 (en) Aloe suppositories
KR101302225B1 (ko) 생약제재를 주재로한 피부질환 예방 및 치료용 약학적 조성물 또는 면역증강용 건강기능성식품 조성물
Mees et al. Maytenus robusta Reissek, a medicinal plant popularly used to treat digestive diseases, promotes ameliorative effects in colon and liver of mice exposed to dextran sulfate sodium
CN104623457B (zh) 缩阴排毒祛斑凝胶剂及其制备方法
KR102157247B1 (ko) 김 추출물을 함유하는 가려움증의 개선, 예방 또는 치료용 조성물
Panda Aloe vera handbook cultivation, research finding, products, formulations, extraction & processing
KR102506493B1 (ko) 민물김 추출물 또는 이의 분획물을 유효성분으로 포함하는 부종 예방 또는 치료용 조성물
ITRM20130542A1 (it) Nuove frazioni di estratti di liquirizia e loro usi
CN117838759A (zh) 治疗溃疡性结肠炎的连翘叶有效部位及其制备方法和应用
RU2245161C1 (ru) Контактное слабительное средство, фармацевтическая композиция на его основе и способ профилактики и лечения запоров и нарушений биоритма дефекации
KR20160078212A (ko) 미나리 에탄올 추출물의 분획물을 유효성분으로 함유하는 염증성 질환 예방 또는 개선용 조성물
Al-Snafi The efficacy and safety of medicinal plants documented by clinical trials (part 1)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120314

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

17Q First examination report despatched

Effective date: 20130130

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/14 20060101ALI20130404BHEP

Ipc: A61K 36/63 20060101AFI20130404BHEP

Ipc: A61K 36/33 20060101ALI20130404BHEP

Ipc: A61K 9/00 20060101ALI20130404BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130524

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 640270

Country of ref document: AT

Kind code of ref document: T

Effective date: 20131215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010011741

Country of ref document: DE

Effective date: 20140109

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2443574

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140219

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20131113

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 640270

Country of ref document: AT

Kind code of ref document: T

Effective date: 20131113

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140213

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140313

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140313

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010011741

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

26N No opposition filed

Effective date: 20140814

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010011741

Country of ref document: DE

Effective date: 20140814

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140901

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140214

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100901

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131113

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602010011741

Country of ref document: DE

Representative=s name: ETL WABLAT & KOLLEGEN PATENT- UND RECHTSANWALT, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602010011741

Country of ref document: DE

Representative=s name: ETL IP PATENT- UND RECHTSANWALTSGESELLSCHAFT M, DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602010011741

Country of ref document: DE

Representative=s name: ETL IP PATENT- UND RECHTSANWALTSGESELLSCHAFT M, DE

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20200915

Year of fee payment: 11

Ref country code: GB

Payment date: 20200902

Year of fee payment: 11

Ref country code: DE

Payment date: 20200903

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20200907

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20201007

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602010011741

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210901

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210930

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220401

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20221028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210902